Log in

NASDAQ:BGNEBeigene Stock Price, Forecast & News

$196.03
-3.78 (-1.89 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$192.01
Now: $196.03
$200.46
50-Day Range
$159.12
MA: $177.35
$204.10
52-Week Range
$114.41
Now: $196.03
$210.35
Volume211,400 shs
Average Volume223,089 shs
Market Capitalization$15.25 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.29
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; and BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers. In addition, its clinical stage drugs include BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway; BGB-A333, a humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; BGB-A425, a TIM-3 inhibitor; MGCD-0516, a multi-kinase inhibitor; and CC-122, a cereblon modulator. The company has collaborations with Celgene Corporation, Merck KGaA, Mirati Therapeutics, Inc., Zymeworks, BioAtla, LLC, and Ambrx, Inc. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.
Read More
Beigene logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.15 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BGNE
CUSIPN/A
Phone1-345-949-4123

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$428.21 million
Book Value$15.87 per share

Profitability

Net Income$-948,630,000.00
Net Margins-284.45%

Miscellaneous

Employees3,500
Market Cap$15.25 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive BGNE News and Ratings via Email

Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.

Beigene (NASDAQ:BGNE) Frequently Asked Questions

How has Beigene's stock been impacted by COVID-19 (Coronavirus)?

Beigene's stock was trading at $145.69 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BGNE shares have increased by 34.6% and is now trading at $196.03. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Beigene?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Beigene.

When is Beigene's next earnings date?

Beigene is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Beigene.

How were Beigene's earnings last quarter?

Beigene Ltd (NASDAQ:BGNE) released its earnings results on Monday, May, 11th. The company reported ($4.70) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($4.85) by $0.15. The company had revenue of $52.06 million for the quarter, compared to analysts' expectations of $27 million. Beigene had a negative net margin of 284.45% and a negative return on equity of 68.64%. View Beigene's earnings history.

What price target have analysts set for BGNE?

11 brokers have issued 1 year target prices for Beigene's stock. Their forecasts range from $165.00 to $230.00. On average, they expect Beigene's share price to reach $202.81 in the next year. This suggests a possible upside of 3.5% from the stock's current price. View analysts' price targets for Beigene.

Has Beigene been receiving favorable news coverage?

News articles about BGNE stock have been trending somewhat negative on Saturday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Beigene earned a news sentiment score of -1.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Beigene.

Who are some of Beigene's key competitors?

What other stocks do shareholders of Beigene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beigene investors own include NVIDIA (NVDA), Alibaba Group (BABA), Crispr Therapeutics (CRSP), Square (SQ), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Intuitive Surgical (ISRG), InVitae (NVTA), AbbVie (ABBV) and JD.Com (JD).

Who are Beigene's key executives?

Beigene's management team includes the following people:
  • Mr. John V. Oyler, Co-Founder, CEO & Chairman (Age 51)
  • Dr. Xiaodong Wang, Co-Founder, Chairman of the Scientific Advisory Board & Director (Age 56)
  • Dr. Heng Liang, CFO & Chief Strategy Officer (Age 56)
  • Dr. Jane E. Huang M.D., Chief Medical Officer - Hematology (Age 46)
  • Dr. Xiaobin Wu, Pres & Gen. Mang. of China

When did Beigene IPO?

(BGNE) raised $126 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

What is Beigene's stock symbol?

Beigene trades on the NASDAQ under the ticker symbol "BGNE."

Who are Beigene's major shareholders?

Beigene's stock is owned by a variety of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.01%). Company insiders that own Beigene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang. View institutional ownership trends for Beigene.

Which institutional investors are buying Beigene stock?

BGNE stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. View insider buying and selling activity for Beigene.

How do I buy shares of Beigene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Beigene's stock price today?

One share of BGNE stock can currently be purchased for approximately $196.03.

How big of a company is Beigene?

Beigene has a market capitalization of $15.25 billion and generates $428.21 million in revenue each year. The company earns $-948,630,000.00 in net income (profit) each year or ($15.80) on an earnings per share basis. Beigene employs 3,500 workers across the globe.

What is Beigene's official website?

The official website for Beigene is www.beigene.com.

How can I contact Beigene?

Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.